Literature DB >> 9175907

Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy.

P P Sfikakis, C S Via.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9175907     DOI： 10.1006/clin.1997.4368

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN： 0090-1229


× No keyword cloud information.
  5 in total

1.  Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy.

Authors:  C K Wong; Amy W Y Ho; Peter C Y Tong; C Y Yeung; Juliana C N Chan; Alice P S Kong; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

2.  Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma.

Authors:  C K Wong; S W M Lun; F W S Ko; W K Ip; D S C Hui; C W K Lam
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 3.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

4.  Abatacept: the evidence for its place in the treatment of rheumatoid arthritis.

Authors:  Marcus D Köller
Journal:  Core Evid       Date:  2008-02-29

5.  Candidate Markers for Stratification and Classification in Rheumatoid Arthritis.

Authors:  Lucius Bader; Stein-Erik Gullaksen; Nello Blaser; Morten Brun; Gerd Haga Bringeland; André Sulen; Clara Gram Gjesdal; Christian Vedeler; Sonia Gavasso
Journal:  Front Immunol       Date:  2019-07-05       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.